Dabo Healthcare (002901.SZ) announced semi-annual results, with net profit of 353 million yuan to mother, an increase of 44.65% over the previous year

According to Zhitong Finance App, Dabo Healthcare (002901.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1.34 billion yuan, an increase of 10.69%; achieved net profit attributable to shareholders of listed companies of 353 million yuan, an increase of 44.65%; net profit after deduction of 279 million yuan, an increase of 25.10% year on year; basic earnings per share were 0.8648 yuan.

During the reporting period, the company focused on the development of its main business, continued to deepen the field of medical device innovation such as orthopedics, closely focused on clinical needs, continuously broke through technical barriers, met diversified clinical needs, continuously enhanced product competitiveness and market influence, empowered business development with better products and services, and provided a core driving force for performance growth. During the reporting period, the company's various product lines achieved synergy, and the operating income of the core product line achieved steady growth. Among them, the company's traumatic products achieved revenue of 511 million yuan, an increase of 9.08% year on year; spinal products achieved revenue of 237 million yuan, an increase of 9.19% year on year; and minimally invasive surgical products achieved revenue of 215 million yuan, an increase of 8.93% year on year.